Expression of herpes simplex virus 1 glycoprotein B by a recombinant vaccinia virus and protection of mice against lethal herpes simplex virus 1 infection.

Abstract

The herpes simplex virus 1 (HSV-1) strain F gene encoding glycoprotein gB was isolated and modified at the 5' end by in vitro oligonucleotide-directed mutagenesis. The modified gB gene was inserted into the vaccinia virus genome and expressed under the control of a vaccinia virus promoter. The mature gB glycoprotein produced by the vaccinia virus recombinant was glycosylated, was expressed at the cell surface, and was indistinguishable from authentic HSV-1 gB in terms of electrophoretic mobility. Mice immunized intradermally with the recombinant vaccinia virus produced gBspecific neutralizing antibodies and were resistant to a lethal HSV-1 challenge.

Immune responses to replication-defective HSV-1 type vectors within the CNS: implications for gene therapy

“…7 These are generated against the viral envelope-bound glycoproteins, predominantly glycoproteins B, C, and D (gB, gC, and gD). 8 These antibodies bind to viral particles, and if in sufficiently high circulating levels, have the potential to inhibit viral adhesion and entry and participate in inducing antibody-dependent, cell-mediated cytotoxicity. 9 Despite existing humoral immunity, however, wild-type HSV is proficient in evading the immune system.…”

A Recombinant Vaccinia Virus Expressing Herpes Simplex Virus Type 1 Glycoprotein B Induces Cytotoxic T Lymphocytes in Mice

“…This approach has proved successful in other viral systems (Bennink et al, 1984;Wiktor et al, 1984) and has been used with HSV-1 gD . We have recently constructed a vaccinia virus recombinant (termed vgB 11) expressing HSV-1 gB (Cantin et al, 1987). Glycoprotein B is expressed on the surface of vgBll-infected cells and is electrophoretically and antigenically indistinguishable from gB produced in HSV-l-infected cells.…”

Induction of protective immunity with antibody to herpes simplex virus type 1 glycoprotein H (gH) and analysis of the immune response to gH expressed in recombinant vaccinia virus

“…VgD52 (Cantin et al, 1987;Cremer et al, 1985) express HSV-1 gB and gD, respectively and were kindly provided by the authors. Vac YC3 was used as a negative control for vaccination and expresses a schistosome surface antigen (G. Smith, unpublished results).…”